Please note: Medicare Rebate for this test is subject to conditions. Patients may receive an invoice:

• Medicare (Fully Covered) - MBS 73439 - NSCLC
• Medicare (Fully Covered) - MBS 73433 - NTRK1/2/3
• Medicare (Fully Covered) - MBS 73376 - Sarcoma
• Non-Medicare eligible - $750.00 

For non-Medicare eligible patients - Patient Financial Consent Form must be completed. 

Fee above is an indication only; please contact testing laboratory for up-to date cost.

Kindly be advised that this test should only be requested by, or on behalf of, a specialist or a consultant physician.

Please refer to Molecular Genetics - Austin Pathology for specific testing details and request form for ordering. After this form has been completed, please forward the form via fax/email address found on the request form.

Gene List:
This assay enables comprehensive detection of clinically relevant gene fusions across targeted sequencing of 1,385 cancer-associated genes. Please refer to TruSight RNA Pan-Cancer Target Genes for the full list of genes.

Please note: Due to the recent introduction of this test, the department is currently in the process of obtaining NATA accreditation. Validation of gene expression is in progress and will only be reported if considered likely to significantly impact the diagnosis or clinical management.

• At least 10% tumour nuclei
• 5μm sections on uncoated slides - 7 sections for resection specimens OR
• 10 sections for small biopsies or resections with very focal tumour OR
• FFPE tissue block
  
  
• Copy of the histology or cytology report

Contact Molecular Diagnostics - Genetics on 03 9496 5657 to confirm add on suitability.